Treatment of children from 6 to 11 years old affected by moderate–severe atopic dermatitis with dupilumab: a first perspective from a single‐center real‐life experience in Italy

Colonna, Cristiana; Zussino, Martina; Monzani, Nicola Adriano; Ponziani, Alessandra; Cavalli, Riccardo

doi:10.1111/jdv.17963

Cited by 9 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, this trend at least indicates that the improvement is persistent over time, even if longer-term studies are needed. Finally, we observed a favourable safety profile of dupilumab in children aged 6–11 years in line with previous studies in children, adolescents and adults with moderate-to-severe AD [ 12 , 19 – 22 , 28 – 32 ]. Injection-site reactions and conjunctivitis were the most common AEs.…”

Section: Discussionsupporting

confidence: 91%

Dupilumab Treatment in Children Aged 6–11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study

et al. 2022

View full text Add to dashboard Cite

Background The management of paediatric atopic dermatitis (AD) is challenging, mostly relying on emollients and topical corticosteroids. Dupilumab, a fully human monoclonal antibody, has been recently approved for the treatment of children aged 6–11 years with moderate-to-severe AD not adequately controlled with topical therapies or when those therapies are not advisable. Objectives The aim of this study was to evaluate in real life the effectiveness and safety of dupilumab in the treatment of children aged from 6 to 11 years. Methods Demographic and clinical data of children aged 6–11 years, affected by moderate-to-severe AD and treated with dupilumab, were retrospectively collected from 24 dermatological and paediatric referral centres. Dupilumab was administered subcutaneously at an induction dose of 300 mg on day (D) 1, followed by 300 mg on D15 and 300 mg every 4 weeks. Disease severity was assessed at baseline and after week 2 (W2), W4 and W16 of dupilumab therapy using Eczema Area Severity Index (EASI), Pruritus Numerical Rating Scale (P-NRS) and Sleep NRS (S-NRS) and Children’s Dermatology Life Quality Index (c-DLQI) score. Results A total of 55 AD children (24 males [43.64%], 31 females [56.36%]; mean age 9.35 ± 1.75 years) were included. A significant improvement in EASI score, P-NRS, S-NRS and c-DLQI was observed from baseline to W16 of treatment with dupilumab. In particular, at W16 the proportion of patients achieving EASI75 was 74.54%. Moreover, at the same timepoint a significant mean percentage reduction for P-NRS, S-NRS and c-DLQI was also observed (68.39%, 70.22% and 79.03%, respectively). Conclusions Our real-life data seem to confirm the effectiveness of dupilumab in paediatric patients on all disease aspects, including extent and severity of signs, intensity of symptoms, sleep and QoL, with a good safety profile.

show abstract

Section: Discussionsupporting

confidence: 91%

Dupilumab Treatment in Children Aged 6–11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Dupilumab is a fully human VelocImmune®‐derived monoclonal antibody 5,6 . There are many research publications regarding dupilumab in pediatric AD patients 7–19 . In 2019 and 2020 dupilumab was successively approved to treat adolescents (12–17 years of age) and children (6–11 years of age) with moderate‐to‐severe AD by the United States food and drug administration (FDA) 20,21 .…”

Section: Introductionmentioning

confidence: 99%

“…5,6 There are many research publications regarding dupilumab in pediatric AD patients. [7][8][9][10][11][12][13][14][15][16][17][18][19] In 2019 and 2020 dupilumab was successively approved to treat adolescents (12-17 years of age) and children (6)(7)(8)(9)(10)(11) years of age) with moderate-to-severe AD by the United States food and drug administration (FDA). 20,21 More recently, the FDA approved dupilumab for the treatment of moderateto-severe AD in children aged 6 months to 5 years old.…”

mentioning

confidence: 99%

Efficacy and safety profile of dupilumab for the treatment of atopic dermatitis in children and adolescents: A systematic review and meta‐analysis

Xu,

Guo,

et al. 2023

Pediatric Dermatology

View full text Add to dashboard Cite

BackgroundDupilumab is the first biologic approved for the treatment of moderate‐to‐severe atopic dermatitis (AD) in children and adolescents. Previous systematic reviews explored the effectiveness and safety of dupilumab in adults with AD. However, the underlying mechanisms of AD can vary among different age groups, emphasizing the need for separate investigation into the use of dupilumab in children and adolescents with AD.ObjectiveTo evaluate the efficacy and safety of dupilumab in children and adolescents with AD based on evidence from clinical trials and observational studies.MethodsThe process of meta‐analysis was conducted according to preferred reporting items for systematic reviews and meta‐analyses guidelines.ResultsSeven clinical trials and 11 observational studies involving 1275 children and adolescents with AD were eligible for quantitative analysis. Overall, the pooled percentages of eczema area and severity index (EASI) 50, EASI 75, EASI 90, EASI 100, and investigator's global assessment (IGA) 0/1 were 72.9% (95% CI: 61.6%–81.9%), 57.4% (48.1%–66.2%), 31.3% (24.0%–39.7%), 29.7% (23.3%–37.0%), and 35.2% (29.3%–41.5%). With prolonged treatment time, an increase was seen in the pooled rate of EASI response, indicating that dupilumab may provide sustained benefits for children and adolescents over the long term. The reported adverse events were primarily mild and manageable, with an overall incidence rate of 7.2% across clinical trials and 7.6% across observational studies.ConclusionDupilumab was an effective and safe treatment option for children and adolescents with AD, with positive results observed from long‐term use and an acceptable safety profile. More long‐term, high‐quality, controlled studies in different regions are needed for further verification.

show abstract

Atopic dermatitis in 32 children treated with dupilumab in real life. A new contribution

Betlloch‐Mas,

Armengol‐García,

Jara‐Rico

et al. 2024

Skin Health and Disease

View full text Add to dashboard Cite

show abstract

Treatment of children from 6 to 11 years old affected by moderate–severe atopic dermatitis with dupilumab: a first perspective from a single‐center real‐life experience in Italy

Cited by 9 publications

References 9 publications

Dupilumab Treatment in Children Aged 6–11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study

Dupilumab Treatment in Children Aged 6–11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study

Efficacy and safety profile of dupilumab for the treatment of atopic dermatitis in children and adolescents: A systematic review and meta‐analysis

Atopic dermatitis in 32 children treated with dupilumab in real life. A new contribution

Contact Info

Product

Resources

About